The need for greater SST5 activation for a more complete suppression of GH was confirmed in studies of cultures of pituitary adenoma cells from patients with acromegaly classified as only partially responsive to SRIF analog therapy (Jaquet et al., 2000). The gene discussed is SSTR5; the disease is acromegaly.